EXACT SCIENCES CORP (EXAS) Stock News
NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD
EXAS Latest News, Press Relases and Analysis
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?
Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials.
Mentions: GH
Why Exact Sciences (EXAS) Shares Are Trading Lower Today
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened significantly while revenue trudged along. While EXAS deserves some credit for the modest top-line beat, the company remained unprofitable on a GAAP basis, and this is also wiping out its cash flow headroom as free cash flow margin also fell significantly during the quarter. On the other hand, Exact Sciences blew past analysts' constant currency revenue expectations this quarter, and its adjusted EPS and EBITDA outperformed. Still, we think this was still a mixed yet challenging quarter.
Exact Sciences (EXAS) Q4 2024 Earnings Call Transcript
EXAS earnings call for the period ending December 31, 2024.
Exact Sciences’s (NASDAQ:EXAS) Q4: Beats On Revenue
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s revenue to be around $3.06 billion, close to analysts’ estimates. Its non-GAAP loss of $0.06 per share was 67.9% above analysts’ consensus estimates.
Exact Sciences’s (NASDAQ:EXAS) Q4: Beats On Revenue
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s revenue to be around $3.06 billion, close to analysts’ estimates. Its non-GAAP loss of $0.06 per share was 67.9% above analysts’ consensus estimates.
Exact Sciences Announces Fourth Quarter 2024 Results
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for.
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call
New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone
The company is working to expand the uses and reimbursement for its blood-based tests for cancer.
Exact Sciences Stock Drops 12% Over Four Days. 'What Is Going On?'
The company is facing numerous headline risks. But not all of them are legitimate, says one analyst.
Mentions: ARKK
2 Healthcare Stocks to Buy Hand Over Fist in January
Instead, as long-term investors know, the key is to hold onto excellent companies that can perform well over the long run. Let's consider two in the healthcare sector: DexCom (NASDAQ: DXCM) and Exact Sciences (NASDAQ: EXAS). Let's discuss why these two companies are worth investing in right now.
Mentions: DXCM
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
Exact Sciences to Participate in December Investor Conferences
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
